The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher.The flow of information is constant and sometimes overwhelming on Wall Street. Trying to interpret an onslaught of earnings reports and monthly economic data releases each quarter can easily allow something of importance to go unnoticed.For example, May 15 marked the deadline for institutional investors with at least $100 million in assets under management to file Form 13F with the Securities a ...

Core Insights - Zoetis is positioned to continue its earnings-beat streak, particularly in the upcoming earnings report, with a history of positive surprises in recent quarters [1][5] - The company reported earnings of $1.48 per share for the last quarter, exceeding the Zacks Consensus Estimate of $1.4 per share by 5.71% [2] - The previous quarter also saw a positive surprise, with actual earnings of $1.4 per share against an expected $1.37 per share, resulting in a 2.19% surprise [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +1.10%, indicating bullish sentiment among analysts regarding the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Since its spin-off from Pfizer ( PFE ) in 2012, the New Jersey-based Zoetis Inc. ( ZTS ) has become the most dominant pharmaceutical company engaged in animal health. Approximately 2/3 rd of its revenue isI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating wealth is ...

Company Overview - JPMorgan upgraded Phibro Animal Health Corporation (PAHC) due to strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio, which includes 37 product lines sold in about 80 countries and six manufacturing sites across the U.S., Italy, and China [1] - The acquisition is expected to enhance Phibro's profitability, improve EBITDA margins, and be accretive to adjusted earnings per share [1] Financial Performance - In Q3 2025, Phibro's sales reached $347.8 million, an increase of $84.6 million, or 32% year over year, although it missed the consensus estimate of $352.40 million [3] - Adjusted earnings for the same period were 63 cents, surpassing the consensus of 52 cents [3] Guidance and Market Outlook - Phibro raised its fiscal 2025 adjusted earnings per share guidance from $1.87-$2.01 to $1.96-$2.09, compared to the consensus of $1.94 [4] - The company revised its sales guidance from $1.25 billion-$1.30 billion to $1.26 billion-$1.29 billion, against a consensus of $1.28 billion [4] - Analyst Knyazkova noted that despite a strong performance in PAHC shares this year, there remains a favorable setup for further upside to estimates and attractive valuation [4] Industry Insights - The animal health performance is expected to exceed expectations for 2025, driven by strong demand, price increases, and healthy growth across medicated feed additives, nutritional specialties, and vaccines for 2026 [2] - While growth in livestock is slower than in companion animals, the livestock sector maintains strong fundamentals, including population growth, rising meat consumption, and limited impact from economic shifts [3]

Nearly a year ago, I reviewed Zoetis (NYSE: ZTS ) and stated that the company was a “Buy.” My reasoning was that the company remained a leader in a niche industry and has continued to grow revenue despite someAnalyst’s Disclosure:I/we have a beneficial long position in the shares of ZTS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relatio ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Zoetis (ZTS) .Zoetis currently has an average brokerage recommendation (ABR) of 1.26, on a scal ...

Group 1 - Phibro Animal Health (NASDAQ: PAHC) announced a significant acquisition from Zoetis (ZTS) aimed at driving business momentum [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in IPOs, mergers & acquisitions, earnings reports, and corporate capital allocation [1] - The service covers approximately 10 major events monthly to find optimal investment opportunities [1]

Company Performance - Zoetis (ZTS) closed at $155.06, reflecting a -4.09% change from the previous day, underperforming the S&P 500 which had a daily loss of 0.03% [1] - The stock has decreased by 1.21% over the past month, while the Medical sector gained 1.25% and the S&P 500 increased by 0.6% [1] Upcoming Financial Results - Zoetis is expected to report an EPS of $1.61, indicating a 3.21% increase from the same quarter last year, with projected revenue of $2.4 billion, a 1.67% rise from the previous year [2] - For the full year, earnings are projected at $6.26 per share and revenue at $9.49 billion, representing increases of +5.74% and +2.53% respectively from the prior year [3] Analyst Estimates and Rankings - Recent changes in analyst estimates for Zoetis are crucial as they reflect optimism about the business and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Zoetis at 3 (Hold) [5] Valuation Metrics - Zoetis has a Forward P/E ratio of 25.85, which is a premium compared to the industry average Forward P/E of 16.43 [6] - The company also has a PEG ratio of 2.68, while the Medical - Drugs industry average PEG ratio is 1.67 [6] Industry Context - The Medical - Drugs industry, part of the Medical sector, holds a Zacks Industry Rank of 79, placing it in the top 33% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Our Purpose April 2025 To nurture the world and humankind by advancing care for animals. Our Vision To be the most trusted and valued animal health company, shaping the future of animal care through our innovation, customer obsession and purpose-driven colleagues. 2 Zoetis Corporate Overview 2 Corporate Overview Zoetis at a Glance 70+ Years of experience $9.3B Annual revenue 7 Major product categories 8 Core species We provide: 100+ Countries with market presence 23 Manufacturing sites 68% Revenue from comp ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...